MMP7
ENSG00000137673
Target class
Enzyme
Chromosome
11
Approved drugs
3
Clinical candidates (approved and in development)
4
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Other names
- PUMP-1
- Target name
- MMP7
- Gene name
- Matrix metallopeptidase 7
- Gene symbol
- MMP7
- Previous gene symbols
- MPSL1
- Protein name
- Matrilysin (EC 3.4.24.23) (Matrin) (Matrix metalloproteinase-7) (MMP-7) (Pump-1 protease) (Uterine metalloproteinase)
- Gene biotype
- Protein coding
- Gene family
- M10 matrix metallopeptidases|Elastases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 16
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 251.01
- Tissue specificity (Gini)
- 0.882
- Tissue specificity (tau)
- 0.973
- KEGG gene identifiers
- hsa:4316
- Protein interaction confidence
- 0.798614
- Protein interaction partners
- 44
- R-HSA-1442490
- R-HSA-1474228
- R-HSA-1592389
- R-HSA-2022090
- R-HSA-9009391
- End position
- 102530853
- Start position
- 102520508
- Chromosome
- 11
- Strand
- Reverse
- Secreted, extracellular space, extracellular matrix .
- Cytosol
- Nucleoplasm
- Vesicles
- Tissue specificity (tau)
- 0.973189
- Expression inequality (Gini)
- 0.882215
Expression in transcripts per million
- Minor Salivary Gland
- 251.01
- Kidney - Cortex
- 85.52
- Kidney - Medulla
- 48.53
- Skin - Sun Exposed (Lower leg)
- 39.51
- Pancreas
- 34.1
Expression in transcripts per million
- Minor Salivary Gland251.01
- Kidney - Cortex85.52
- Kidney - Medulla48.53
- Skin - Sun Exposed (Lower leg)39.51
- Pancreas34.1
- Skin - Not Sun Exposed (Suprapubic)32.26
- Breast - Mammary Tissue27.12
- Cells - EBV-transformed lymphocytes25.01
- Prostate23.7
- Uterus17.16
- Lung5.6
- Fallopian Tube5.27
- Bladder2.32
- Adipose - Subcutaneous1.48
- Cervix - Endocervix1.34
- Testis1.29
- Liver0.9
- Cells - Cultured fibroblasts0.7
- Vagina0.56
- Small Intestine - Terminal Ileum0.52
- Esophagus - Mucosa0.39
- Cervix - Ectocervix0.38
- Stomach0.29
- Artery - Aorta0.29
- Artery - Coronary0.28
And 29 more, listed on the interactive page.
- GO:0006508
- GO:0006509
- GO:0022617
- GO:0030335
- GO:0030574
- GO:0031293
- GO:0005576
- GO:0070062
- GO:0004175
- GO:0004222
- GO:0004252
- GO:0005515
- GO:0008237
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hMMP7, is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP7 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (335)
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
- A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
- A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease
- A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea
- A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
- A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
- A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
- A Novel Combination Oral Agent to Treat Acne Vulgaris
- A Phase II Study of Doxycycline in Relapsed NHL
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
- A Pilot Study of Inflammatory Markers in Alzheimer's Disease
- A Randomized Controlled Trial of Doxycycline Post Exposure Prophylaxis to Prevent Incident Bacterial STIs Among Women in the United States
- A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions
- A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
- A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations
- A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period
- A Study of Continuous Oral Contraceptives and Doxycycline
Drugs (5)
- Doxycycline Matrix metalloproteinase 7 inhibitor
- Doxycycline anhydrous Matrix metalloproteinase 7 inhibitor
- Doxycycline calcium Matrix metalloproteinase 7 inhibitor
- Doxycycline hyclate Matrix metalloproteinase 7 inhibitor
- Marimastat Matrix metalloproteinase 7 inhibitor